GSK plc (NYSE:GSK) Shares Sold by Sei Investments Co.

Sei Investments Co. decreased its position in shares of GSK plc (NYSE:GSK) by 12.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 823,210 shares of the pharmaceutical company’s stock after selling 122,138 shares during the quarter. Sei Investments Co.’s holdings in GSK were worth $27,841,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of GSK. Sunbelt Securities Inc. raised its position in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the last quarter. Indiana Trust & Investment Management Co increased its stake in shares of GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after acquiring an additional 500 shares during the period. Crews Bank & Trust purchased a new position in shares of GSK during the fourth quarter worth $26,000. ST Germain D J Co. Inc. lifted its position in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the period. Finally, Sierra Ocean LLC purchased a new stake in GSK in the fourth quarter valued at $32,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Trading Up 0.2 %

GSK stock opened at $38.65 on Wednesday. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.93. The company’s 50-day simple moving average is $36.90 and its 200-day simple moving average is $36.80. The firm has a market cap of $80.00 billion, a P/E ratio of 24.31, a PEG ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, equities analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.07%. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is currently 98.74%.

Analyst Ratings Changes

A number of equities analysts have weighed in on GSK shares. Morgan Stanley initiated coverage on GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.